Biogen (NASDAQ:BIIB) Stock Sale Revealed by Rep. Maria Elvira Salazar

Key Points

• Rep. Maria Elvira Salazar sold Biogen shares worth between $1,001 and $15,000 on September 24 from her UBS IRA account, along with similarly sized positions in several other companies.
• Biogen shares were trading at $218.43, down 1.7%, while the company reported quarterly results above expectations: EPS of $3.60 versus a $2.94 consensus and revenue of $2.74 billion.
• Analysts maintain a generally positive view, with a “Moderate Buy” consensus and an average price target of $230; institutional investors own approximately 87.93% of Biogen’s stock.

Representative Maria Elvira Salazar (Republican-Florida) recently sold shares of Biogen Inc. NASDAQ: BIIB. In a filing disclosed on October 7th, the Representative disclosed that they had sold between $1,001 and $15,000 in Biogen stock on September 24th. The trade occurred in the Representative's "UBS IRA ACCOUNT" account.

Representative Maria Elvira Salazar also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Citigroup NYSE: C on 9/24/2026.
• Sold $1,001 - $15,000 in shares of Chubb NYSE: CB on 9/24/2026.
• Sold $1,001 - $15,000 in shares of Microsoft NASDAQ: MSFT on 9/24/2026.
• Sold $1,001 - $15,000 in shares of GE Aerospace NYSE: GE on 9/24/2026.
• Sold $1,001 - $15,000 in shares of Honeywell International NASDAQ: HON on 9/24/2026.
• Sold $1,001 - $15,000 in shares of Snowflake NYSE: SNOW on 9/24/2026.
• Sold $1,001 - $15,000 in shares of FedEx NYSE: FDX on 9/24/2026.
• Sold $1,001 - $15,000 in shares of Salesforce NYSE: CRM on 9/24/2026.
• Sold $1,001 - $15,000 in shares of RH NYSE: RH on 9/24/2026.
• Sold $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 9/24/2026.

Biogen Trading Down 1.7%

NASDAQ BIIB opened at $218.43 on Friday. The company has a fifty day moving average of $216.95 and a 200 day moving average of $202.10. The company has a market capitalization of $32.27 billion, a PE ratio of 38.66, a P/E/G ratio of 2.45 and a beta of 0.09. Biogen Inc. has a 1 year low of $138.00 and a 1 year high of $230.49. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.87 and a quick ratio of 1.26.

Biogen (NASDAQ:BIIB - Get Free Report) last posted its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.94 by $0.66. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The firm had revenue of $2.74 billion during the quarter, compared to analysts' expectations of $2.46 billion. During the same period in the previous year, the business posted $5.47 EPS. The business's revenue was up 3.4% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Research analysts forecast that Biogen Inc. will post 12.41 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of BIIB. BlackRock Inc. purchased a new stake in shares of Biogen during the second quarter worth approximately $3,453,878,000. Primecap Management Co. CA purchased a new stake in Biogen during the 2nd quarter valued at about $3,274,304,000. Wellington Management Group LLP raised its holdings in Biogen by 5.3% in the 2nd quarter. Wellington Management Group LLP now owns 3,117,469 shares of the biotechnology company's stock valued at $673,560,000 after acquiring an additional 155,828 shares during the last quarter. Amundi lifted its stake in Biogen by 91.8% in the 2nd quarter. Amundi now owns 1,516,831 shares of the biotechnology company's stock worth $327,727,000 after purchasing an additional 726,004 shares in the last quarter. Finally, Legal & General Group Plc acquired a new stake in shares of Biogen in the second quarter valued at approximately $322,640,000. 87.93% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have weighed in on BIIB. Morgan Stanley upped their price objective on shares of Biogen from $222.00 to $231.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 30th. HC Wainwright lifted their price target on Biogen from $237.00 to $251.00 and gave the company a "buy" rating in a research note on Thursday, July 30th. Guggenheim upped their price target on Biogen from $260.00 to $280.00 and gave the stock a "buy" rating in a report on Tuesday, July 21st. Truist Financial upgraded Biogen from a "hold" rating to a "buy" rating and increased their price target for the stock from $190.00 to $235.00 in a research report on Monday, July 13th. Finally, Needham & Company LLC raised their price objective on Biogen from $255.00 to $256.00 and gave the company a "buy" rating in a report on Monday, June 29th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Biogen presently has an average rating of "Moderate Buy" and a consensus target price of $230.00.

About Representative Salazar

Maria Elvira Salazar (Republican Party) is a member of the U.S. House, representing Florida's 27th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027. Salazar (Republican Party) ran for re-election to the U.S. House to represent Florida's 27th Congressional District. She won in the general election on November 5, 2024. Maria Elvira Salazar was born in Miami, Florida, and lives in Coral Gables, Florida. Salazar earned an undergraduate degree from the University of Miami in 1983 and a graduate degree from Harvard University in 1995. Her career experience includes working as a television journalist, reporter, and news anchor.

About Biogen

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for serious neurological and neurodegenerative diseases. Its research focuses on conditions including multiple sclerosis, spinal muscular atrophy, Alzheimer's disease, amyotrophic lateral sclerosis and rare neuromuscular disorders.

Biogen's products include Spinraza (nusinersen) for spinal muscular atrophy, Tysabri (natalizumab) and Tecfidera (dimethyl fumarate) for multiple sclerosis, Qalsody (tofersen) for a genetically defined form of ALS, and Skyclarys (omaveloxolone) for Friedreich's ataxia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.